CovidenceID,aveAge (years),aveHeight (cm),aveWeight (kg)," Number of subjects, N", Muscle,Type,Gender,Voluntary (V) or Stimulated (S),aveVol (cm3),aveFL (cm),avePCSA (cm2),aveTorque (Nm),aveForce (N),aveST (N/cm2),Muscle volume method,Fascicle length method,Pennation angle method,CSA,PCSA method,Torque method,Moment arm method,Force method,Specific Tension method,Overall note, Miscellaneous,Score,Age type,Training type,Muscle,name,fast/slow,Joint type,antigrav/grav,Joint action,secondary joint action,anatomical location,newScore
4162,23,176,70.6,16,QF,YNG,M,V,,9.06,231,262,5555,29,"MRI, CSA x slice interval",US at MVC,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,4,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,23
4162,22,167,61.2,15,QF,YNG,F,V,,8.66,175,182,4921,32,"MRI, CSA x slice interval",US at MVC,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,4,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,23
4162,72,174,78.9,20,QF,OLD,M,V,,9.5,174,164,3472,24,"MRI, CSA x slice interval",US at MVC,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,4,OLD,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,23
4162,71,160,67.3,20,QF,OLD,F,V,,8.84,130,116,2928,27,"MRI, CSA x slice interval",US at MVC,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,4,OLD,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,23
4135,72.7,169.3,78.4,11,PF,OLD UT EXP,M,,,,,110.5,2472.8,,,,,,,,,,,,,0,OLD,Untrained,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,26
4135,72.7,169.3,78.4,11,GL,OLD UT EXP,M,V,132.9,4.9,27.2,,262.9,8.9,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,"method of estimating
the relative contribution of each constituent muscle to
the total tendon force component from relative PCSA of
each constituent of a muscle group. We have previously determined
that the GL constitutes 11% of the triceps surae PCSA
(Morse et al. 2005a), and the triceps surae group was estimated
to represent 91% of the total PF PCSA in the elderly
(Wickiewicz et al. 1983); hence this seems to justify the assumption that the triceps surae PCSA represents
the main PCSA of the plantarXexors",,2,OLD,Untrained,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,26
4135,72.7,169.3,78.4,11,PF,OLD T EXP,M,,,,,142.8,3202,,,,,,,,,,,,,0,OLD,Trained,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,26
4135,72.7,169.3,78.4,11,GL,OLD T EXP,M,V,161.8,5.2,31.8,,343.5,11.2,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,,,2,OLD,Trained,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,26
4135,73.9,170.4,72.8,8,PF,OLD UT Control,M,,,,,107.8,2378.5,,,,,,,,,,,,,0,OLD,Untrained,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,17
4135,73.9,170.4,72.8,8,GL,OLD UT Control,M,V,129.8,5.2,27.1,,254.6,9.8,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,,,2,OLD,Untrained,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,17
4135,73.9,170.4,72.8,8,PF,OLD T Control,M,,,,,111.7,2466.9,,,,,,,,,,,,,0,OLD,Untrained,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,17
4135,73.9,170.4,72.8,8,GL,OLD T Control,M,V,133.6,5,28.5,,263.3,9.5,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,,,2,OLD,Untrained,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,17
4128,30,,,7,BIC,YNG ,M,V,,,,4056.6,,53.407,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,each muscle moment contribution was based on relative (PCSA x MA),,7,YNG,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,17
4128,30,,,7,BRA,YNG ,M,V,,,,1598.6,,56.51,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,,,7,YNG,Normal,BRA,Brachialis,Fast,monoarticular,non-antigravity,elbow flexor,,Upper arm,17
4128,30,,,7,BRD,YNG ,M,V,,,,2106,,53.452,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,,,7,YNG,Normal,BRD,Brachioradialis,60/40,monoarticular,non-antigravity,elbow flexor,,Upper arm,13
4128,30,,,9,BIC,YNG ,F,V,,,,2118.3,,50.476,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,,,7,YNG,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,13
4128,30,,,9,BRA,YNG ,F,V,,,,783.6,,53.409,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,,,7,YNG,Normal,BRA,Brachialis,Fast,monoarticular,non-antigravity,elbow flexor,,Upper arm,13
4128,30,,,9,BRD,YNG ,F,V,,,,939.5,,50.519,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,,(Muscle vol/Fiber length)*cos(θ),max MVC,"MRI at rest, JA correction",Tendon Force using relative (PCSA x MA),Force/rPCSA,,,7,YNG,Normal,BRD,Brachioradialis,60/40,monoarticular,non-antigravity,elbow flexor,,Upper arm,13
4127,24.3,172.8,67.5,30,EF,YNG,M,V,257,,18.2,61.1,265,14.7,"MRI, CSA x slice interval",,,ACSA,"MRI, max ACSA",max MVC,Limb length,External Force (Limb Force),Force/ACSA,"The TQ was converted to F by dividing it by the forearm
length (the distance from the head of radius to the processus
styloideus) of each subject",,4,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,18
4127,23.4,161.3,53.6,22,EF,YNG,F,V,139,,10.3,31.9,150,14.7,"MRI, CSA x slice interval",,,ACSA,"MRI, max ACSA",max MVC,Limb length,External Force (Limb Force),Force/ACSA,,,4,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,15
4127,68.5,165.9,65.2,19,EF,OLD,M,V,207,,16.2,48.9,216,13.4,"MRI, CSA x slice interval",,,ACSA,"MRI, max ACSA",max MVC,Limb length,External Force (Limb Force),Force/ACSA,,,4,OLD,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,18
4127,67.5,152.8,51.6,32,EF,OLD,F,V,114,,9.7,26.2,127,13.1,"MRI, CSA x slice interval",,,ACSA,"MRI, max ACSA",max MVC,Limb length,External Force (Limb Force),Force/ACSA,,,4,OLD,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,15
2995,22.6,177,76,20,EF,YNG,M,V,375,,28.2,,331,11.8,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,ACSA,Muscle vol/Fiber length,"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/PCSA,"The biceps brachii, brachialis, and brachioradialis muscles were traced in each image and together
made up the EFs. The triceps brachii and anconeus were traced and together made up the EEs. The pronator teres and
the extensor carpi radialis longus muscles, which together generate 15% of EF torque (38), were not included in the EF
volume because they were not clearly visible in the images over their entire length. The brachioradialis, extensor carpi
radialis longus, and brevis muscles were traced as a group. The brachioradialis volume was then estimated to be 39% of
the combined volume of these three muscles (4). The length of the brachioradialis, however, could be determined because
the origin and insertion regions were clearly evident in all images. The coracobrachialis muscle was traced as part of the
biceps brachii because these two muscles could not be separated convincingly throughout their entire length. In both
young and old cadavers, the coracobrachialis is 23% of the weight of the biceps brachii plus the coracobrachialis (47). To
exclude the coracobrachialis from the EF volume, the biceps brachii volume was reduced by 23% in all subjects. No data
are available for the fiber length-to-muscle length ratio in the anconeus, so it was assumed to be the same as the biceps
brachii because the fibers run parallel in both muscles ",Did not claim specific tension. not all EE or EF muscles included in volume/length measurement,1,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,18
2995,22.6,177,76,20,EE,YNG,M,V,444,,53,,292,5.5,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/rPCSA,,,3,YNG,Normal,EE,Elbow Extendors,Fast,mixed,non-antigravity,elbow extensor,,Upper arm,15
2995,22.6,177,76,20,EF,YNG,M,V,,,20.2,,,16.5,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/PCSA,,,1,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,18
2995,22.6,177,76,20,EE,YNG,M,V,,,28.3,,,10.3,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/rPCSA,,,3,YNG,Normal,EE,Elbow Extendors,Fast,mixed,non-antigravity,elbow extensor,,Upper arm,11
2995,81,176,80,13,EF,OLD,M,V,297,,22.9,,241,10.5,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/PCSA,,,1,OLD,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,11
2995,81,176,80,13,EE,OLD,M,V,323,,38.1,,197,5.1,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/rPCSA,,,3,OLD,Normal,EE,Elbow Extendors,Fast,mixed,non-antigravity,elbow extensor,,Upper arm,24
2995,81,176,80,13,EF,OLD,M,V,,,16.9,,,14.3,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/PCSA,,,1,OLD,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,24
2995,81,176,80,13,EE,OLD,M,V,,,20.9,,,9.5,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",,External Force (Limb Force),Force/rPCSA,,,3,OLD,Normal,EE,Elbow Extendors,Fast,mixed,non-antigravity,elbow extensor,,Upper arm,26
2837,36,165,67.6,32,TS,MID UT,F,,628,0.06,291.2,,568.2,1.97,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),,,External Force (Limb Force),Force/rPCSA,"This design minimized contributions from the foot muscles when
measuring force output during plantar flexor MVC",,3,MID,Untrained,TS,Triceps Surae,Slow,mixed,antigravity,ankle plantar flexor,,Lower leg,26
2837,36,165,67.6,32,TS,MID UT,F,,628,,39.9,,568.2,14.3,,,Literature value,ACSA,"MRI, max ACSA",,,External Force (Limb Force),Force/ACSA,,,3,MID,Untrained,TS,Triceps Surae,Slow,mixed,antigravity,ankle plantar flexor,,Lower leg,26
2837,34,165,55.6,7,TS,YNG T,F,,730.9,,337.2,,637.7,1.87,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),,,External Force (Limb Force),Force/rPCSA,,,3,YNG,Trained,TS,Triceps Surae,Slow,mixed,antigravity,ankle plantar flexor,,Lower leg,26
2837,34,165,55.6,7,TS,YNG T,F,,730.9,,44.7,,637.7,14,,,Literature value,ACSA,"MRI, max ACSA",,,External Force (Limb Force),Force/ACSA,,,3,YNG,Trained,TS,Triceps Surae,Slow,mixed,antigravity,ankle plantar flexor,,Lower leg,27
2833,25,176,73,52,QF,YNG UT,M,V,1838.2,106.4,174.4,,5576,33.3,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Coactivation correction","MRI at rest, JA correction",Tendon Force ,Force/rPCSA,"There was 8% greater ST of the quadriceps in LTT
than UT (33.3   4.5 N·cm2 vs 36.1   5.3 N·cm2; P   0.04,
ES   0.6; Fig. 4A) when accounting for antagonist coactivation,
corrected PTMA, and QEFFPCSA",,3,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,27
2833,25,176,73,52,VM,YNG UT,M,,441.4,104,,,,,,,,,,,,,,,,0,YNG,Untrained,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,17
2833,25,176,73,52,VI,YNG UT,M,,546.9,100.9,,,,,,,,,,,,,,,,0,YNG,Untrained,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,17
2833,25,176,73,52,VL,YNG UT,M,,609.8,111.1,,,,,,,,,,,,,,,,0,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,17
2833,25,176,73,52,RF,YNG UT,M,,240.2,109,,,,,,,,,,,,,,,,0,YNG,Untrained,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,17
2833,22,183,91,16,QF,YNG T,M,V,2881.9,118,245.7,,8564,36.1,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Coactivation correction","MRI at rest, JA correction",Tendon Force ,Force/rPCSA,,,3,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,20
2833,22,183,91,16,VM,YNG T,M,,691,117.1,,,,,,,,,,,,,,,,0,YNG,Trained,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,20
2833,22,183,91,16,VI,YNG T,M,,846.4,107.5,,,,,,,,,,,,,,,,0,YNG,Trained,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,20
2833,22,183,91,16,VL,YNG T,M,,964.3,125.7,,,,,,,,,,,,,,,,0,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,28
2833,22,183,91,16,RF,YNG T,M,,374.5,121.6,,,,,,,,,,,,,,,,0,YNG,Trained,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,28
2821,25,172,73,9,VL,YNG UT,M,V,1892,8.31,75.6,224,,23.1,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",US at MVC JA,Tendon Force using relative PCSA,Force/rPCSA,"Ft and k represent tendon force and relative
contribution of VL to the quadriceps femoris muscles
in terms of physiological cross-sectional area, and
MA is the moment arm length of quadriceps femoris
muscles at 90° of knee fl exion, which is estimated
from the thigh length of each participant (Kubo et
al., 2001)",co activation of BF measured,1,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,19
2821,25,172,73,9,VL,YNG T,M,V,2032,8.54,81.3,241,,23.9,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",US at MVC JA,Tendon Force using relative PCSA,Force/rPCSA,,,1,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,19
2821,25,172,73,9,VL,YNG UT,M,V,1878,8.42,74.5,225,,23.8,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",US at MVC JA,Tendon Force using relative PCSA,Force/rPCSA,,,1,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,26
2821,25,172,73,9,VL,YNG T,M,V,2011,8.61,79,262,,25.1,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",US at MVC JA,Tendon Force using relative PCSA,Force/rPCSA,,,1,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,21
2680,20.1,176.9,76.1,17,QF,YNG UT,M,V,2074,,231,269,6296,29.5,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,method 1 of Erksine 2009,,1,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,26
2680,20.1,176.9,76.1,17,VL,YNG UT,M,,677,8.8,,,,,,,,,,,,,,,pennation angle: 16.2 ± 2.4,0,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,21
2680,20.1,176.9,76.1,17,VI,YNG UT,M,,586,10.3,,,,,,,,,,,,,,,pennation angle: 13.2 ± 3.2,0,YNG,Untrained,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,27
2680,20.1,176.9,76.1,17,RF,YNG UT,M,,345,7.2,,,,,,,,,,,,,,,pennation angle: 26.5 ± 4.6,0,YNG,Untrained,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,19
2680,20.1,176.9,76.1,17,VM,YNG UT,M,,466,10.3,,,,,,,,,,,,,,,pennation angle: 24.5 ± 6.8,0,YNG,Untrained,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,28
2680,20.1,176.9,76.1,17,QF,YNG T,M,V,2188,,245,350,8023,35.5,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,1,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,28
2680,20.1,176.9,76.1,17,VL,YNG T,M,,704,8.8,,,,,,,,,,,,,,,pennation angle: 16.9 ± 2.4,0,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,28
2680,20.1,176.9,76.1,17,VI,YNG T,M,,609,10.4,,,,,,,,,,,,,,,pennation angle: 13.8 ± 3.1,0,YNG,Trained,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,28
2680,20.1,176.9,76.1,17,RF,YNG T,M,,375,7.4,,,,,,,,,,,,,,,pennation angle: 27.0 ± 4.2,0,YNG,Trained,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,20
2680,20.1,176.9,76.1,17,VM,YNG T,M,,500,10.3,,,,,,,,,,,,,,,pennation angle: 24.9 ± 7.4,0,YNG,Trained,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,20
2677,29,171,63,4,BIC,YNG ,M,V,181,20,9.1,28.2,660.3,72.3,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,max MVC,MRI at MVC JA,Tendon Force using relative (PCSA x MA),Force/PCSA,,The relative contribution of each elbow flexor muscle to the flexion torque was calculated by PCSA times the moment arm (An et al. 1981; Edgerton et al. 1986). The BRA had a greater contribution (47%) than that of BIC (34%) and BRD (19%),3,YNG,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,20
2677,29,171,63,4,BRA,YNG ,M,V,152,12,12.7,20.4,910.9,72.3,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,max MVC,MRI at MVC JA,Tendon Force using relative (PCSA x MA),Force/PCSA,,,3,YNG,Normal,BRA,Brachialis,Fast,monoarticular,non-antigravity,elbow flexor,,Upper arm,25
2677,29,171,63,4,BRD,YNG ,M,V,39,12,3.2,11.41,226.4,71.9,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,PCSA,Muscle vol/Fiber length,max MVC,MRI at MVC JA,Tendon Force using relative (PCSA x MA),Force/PCSA,,,3,YNG,Normal,BRD,Brachioradialis,60/40,monoarticular,non-antigravity,elbow flexor,,Upper arm,15
2677,29,171,63,4,EF,YNG ,M,V,,,25,59.9,1819.5,72.7,"MRI, CSA x slice interval",MRI muscle length x literature ratio,,ACSA,Muscle vol/Fiber length,max MVC,MRI at MVC JA,Tendon Force ,Force/PCSA,"As for elbow flexors, averaged values of the moment arms of
agonists were calculated (weighed by the relative PCSA to total)
and considered the representative moment arm for all the flexors.",,3,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,22
2677,29,171,63,4,EE,YNG ,M,V,388,8,46.8,67.7,3008.6,65.4,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC,MRI at MVC JA,Tendon Force ,Force/rPCSA,,,5,YNG,Normal,EE,Elbow Extendors,Fast,mixed,non-antigravity,elbow extensor,,Upper arm,22
2664,20,178,74,42,QF,YNG UT,M,V,2084,8.9,238,248,5809,25.9,"MRI, ACSA & literature regression relationship",US at MVC rep muscle,measured PA representative muscle,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,VL lf and pennation assumed for QF (Erskine method2), Method 2 ,1,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,22
2664,20,178,178,42,QF,YNG T,M,V,2200,8.9,253,315,7152,30.3,"MRI, ACSA & literature regression relationship",US at MVC rep muscle,measured PA representative muscle,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,, Method 2 ,1,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,22
2664,20,178,178,17,QF,YNG UT,M,V,2116,9.1,235,244,5896,26.5,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,,Method 1- more detailed. individual muscle volume measured from multiple MRI scans and individual fiber length,2,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,22
2664,20,178,74,17,QF,YNG T,M,V,2237,9,252,315,7316,30.8,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,, Method 1 ,2,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,22
2653,20,178,77,53,QF,YNG UT,M,V,2080,8.9,237,246,5722,25.6,"MRI, ACSA & literature regression relationship",US at MVC rep muscle,measured PA representative muscle,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,lf and pennation angle of VL used for entire QF,,2,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,26
2653,20,178,77,53,QF,YNG T,M,V,2201,8.9,251,310,6968,29.8,"MRI, ACSA & literature regression relationship",US at MVC rep muscle,measured PA representative muscle,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,,,2,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,26
2651,28,175,75,6,SOL,YNG ,M,S,497,3,161.7,107,2427,15,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC from stimulation, Coactivation correction",MRI at MVC JA,Tendon Force ,Force/rPCSA,,Method A  tendon force=1783 ± 18,1,YNG,Normal,Sol,Soleus,Slow,monoarticular,antigravity,ankle plantar flexor,,Lower leg,7
2651,28,175,75,6,SOL,YNG ,M,V,,1.9,264,121.5,2745,10.4,"MRI, CSA x slice interval",Literature value,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Gravity correction",MRI at rest,Tendon Force ,Force/rPCSA,,Method B  tendon force=2470 ± 176,7,YNG,Normal,Sol,Soleus,Slow,monoarticular,antigravity,ankle plantar flexor,,Lower leg,7
2651,28,175,75,6,TA,YNG ,M,S,152.7,4.8,31.5,22.5,487,15.5,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC from stimulation, Coactivation correction",MRI at MVC JA,Tendon Force ,Force/rPCSA,,Method A  tendon force=458 ± 36,1,YNG,Normal,TA,Tibialis Anterior,Slow,monoarticular,non-antigravity,ankle dorsiflexor,,Lower leg,24
2651,28,175,75,6,TA,YNG ,M,V,,7.5,20.3,44.7,1337,65.8,"MRI, CSA x slice interval",Literature value,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Gravity correction",MRI at rest,Tendon Force ,Force/rPCSA,,Method B  tendon force=1324 ± 110,7,YNG,Normal,TA,Tibialis Anterior,Slow,monoarticular,non-antigravity,ankle dorsiflexor,,Lower leg,24
2649,21.3,177,76.2,27,QF,YNG ,M,V,2054,9.4,226,264,6335,30.3,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,, Method 1 ,1,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,24
2649,21.3,177,76.2,27,QF,YNG ,M,V,2117,9.1,236,264,6335,29.1,"MRI, ACSA & literature regression relationship",US at MVC rep muscle,measured PA representative muscle,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force ,Force/rPCSA,VL muscle geometry at MVC was assumed to be representative of the mean QF architecture, Method 2 ,2,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,24
2649,21.3,177,76.2,27,VL,YNG ,M,,674,9.1,75.1,,,,,,,PCSA,,,,,,,,0,YNG,Normal,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,24
2649,21.3,177,76.2,27,VI,YNG ,M,,580,10.5,56.5,,,,,,,PCSA,,,,,,,,0,YNG,Normal,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,24
2649,21.3,177,76.2,27,RF,YNG ,M,,339,6.9,49.8,,,,,,,PCSA,,,,,,,,0,YNG,Normal,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,17
2649,21.3,177,76.2,27,VM,YNG ,M,,461,10.5,44.4,,,,,,,PCSA,,,,,,,,0,YNG,Normal,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,17
2648,28.2,180,78.8,10,QF,YNG ,M,V,2052.7,,231.8,328.85,11439,55.02,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,,,1,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,17
2648,27.4,167,64,10,QF,YNG ,F,V,1359.2,,162.8,214.74,8695,57.3,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,,,1,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,17
2648,8.9,138,35.6,10,QF,CHD ,B,V,708.6,,104.6,110.6,5234,54.06,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,,,1,CHD,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,17
2648,9.3,141,41.9,10,QF,CHD ,G,V,793.8,,108.2,142.6,6117,59.77,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force ,Force/rPCSA,,,1,CHD,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,20
2646,33.5,176.9,75,8,,YNG ,M,,,,,,,,,,,,,,,,,,"Plantar flexors: MG, LG, Sol, FHL, TP, FDL, PL, PB. 
Dorsiflexors: TA, EDL, Pop",0,YNG,Normal,,,,,,,,,16
2646,33.5,176.9,75,8,GM,YNG ,M,,249.9,23.5,70.8,,,,,,,PCSA,,,,,,,muscle length,0,YNG,Normal,GM,Gastrocnemius Medialis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,16
2646,33.5,176.9,75,8,GL,YNG ,M,,144.9,21.8,28.3,,,,,,,PCSA,,,,,,,muscle length,0,YNG,Normal,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,21
2646,33.5,176.9,75,8,SOL,YNG ,M,,503.5,32.4,247.6,,,,,,,PCSA,,,,,,,muscle length,0,YNG,Normal,Sol,Soleus,Slow,monoarticular,antigravity,ankle plantar flexor,,Lower leg,21
2646,33.5,176.9,75,8,TS,YNG ,M,V,898.3,25.9,346.7,,,10.8,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC,MRI at rest,Tendon Force ,Force/rPCSA,,muscle length,6,YNG,Normal,TS,Triceps Surae,Slow,mixed,antigravity,ankle plantar flexor,,Lower leg,21
2646,33.5,176.9,75,8,PF,YNG ,M,V,1234,,434.6,174.7,3623,8,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC,MRI at rest,Tendon Force ,Force/rPCSA,,Peak torque,6,YNG,Normal,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,21
2646,33.5,176.9,75,8,TA,YNG ,M,,151.4,30,19.7,,,,,,,PCSA,,,,,,,muscle length,0,YNG,Normal,TA,Tibialis Anterior,Slow,monoarticular,non-antigravity,ankle dorsiflexor,,Lower leg,8
2646,33.5,176.9,75,8,EDL,YNG ,M,,114.5,33.8,14.9,,,,,,,PCSA,,,,,,,muscle length,0,YNG,Normal,,,,,,,,,7
2646,33.5,176.9,75,8,DF,YNG ,M,V,265.9,,34.6,32.9,832,24.5,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC,MRI at rest,Tendon Force ,Force/rPCSA,,Peak torque,6,YNG,Normal,DF,Dorsiflexor,Slow,monoarticular,non-antigravity,ankle dorsiflexor,,Lower leg,7
4196,,,,12,GRA,OLD ,Mixed,,,12.9,13.1,,,17.1,3D photogrammetry reconstruction,Directly measured muscle length & literature FWHM-optimal fiber length relationship,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),,,Tendon Force activation correction,Force/rPCSA,Measured force corrected for submax activation,,3,OLD,Normal,GRA,Gracilis,Slow,biarticular,non-antigravity,hip adductor, knee flexor,Lower leg,7
4106,38,176,67.8,6,GM,MID ,M,,245.9,3.29,62.5,,448,13.3,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),,,External Force (Limb Force),Force/rPCSA,,"fiber length at rest: 5.08 ± 0.36

PCSA at rest: 46.5 ± 5.7

ST at rest: 9.6",0,MID,Normal,GM,Gastrocnemius Medialis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,7
4106,38,176,67.8,6,PF,MID ,M,,,,,755.3,2489,,,,,,,,,,,,,0,MID,Normal,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,7
4070,74.3,163,69.7,9,VL,OLD UT EXP,Mixed,V,254.3,8.4,30.4,,847.9,27,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, JA correction","Tendon force, % contribution from literature",Force/rPCSA,"Volume of the entire VL muscle was calculated by summing up all
of the inter-ACSA volumes that was approximated by truncated cone.VL muscle to the patella tendon
force calculated from Eq. 1 was estimated from the relative PCSA of
the VL muscle with respect to the entire quadriceps muscle group,
from the data of Narici et al. ",,3,OLD,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4070,74.3,163,69.7,9,QF,OLD UT EXP,Mixed,,,,,121.4,,,,,,,,,,,,,,0,OLD,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4070,74.3,163,69.7,9,VL,OLD T EXP,Mixed,V,270.3,9.3,29.1,,939.3,32.1,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, JA correction","Tendon force, % contribution from literature",Force/rPCSA,,,3,OLD,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4070,74.3,163,69.7,9,QF,OLD T EXP,Mixed,,,,,131.1,,,,,,,,,,,,,,0,OLD,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4070,67.1,168,73.5,9,VL,OLD UT Control,Mixed,V,291,8.4,34.5,,791.5,23.6,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, JA correction","Tendon force, % contribution from literature",Force/rPCSA,,,3,OLD,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4070,67.1,168,73.5,9,QF,OLD UT Control,Mixed,,,,,122.2,,,,,,,,,,,,,,0,OLD,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4070,67.1,168,73.5,9,VL,OLD T Control,Mixed,V,291.1,8.6,34.1,,717.2,21.5,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, JA correction","Tendon force, % contribution from literature",Force/rPCSA,,,3,OLD,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4070,67.1,168,73.5,9,QF,OLD T Control,Mixed,,,,,108.2,,,,,,,,,,,,,,0,OLD,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4040,25.3,176,79.1,12, PF,YNG ,M,,,,,179,3865,,,,,,,,,,,,,0,YNG,Normal,,,,,,,,,
4040,25.3,176,79.1,12,GL,YNG ,M,V,178.9,5.5,32.3,,416.2,13.1,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Coactivation correction","MRI at rest, JA correction",Tendon Force using relative PCSA,Force/rPCSA,"calculated according to
the tendon excursion method.an extrapolation of the MA was made based on the moment arm. it was possible to isolate the GL component
of Achilles tendon force, by attributing the tendon force to the relative
PCSA of the GL within the plantarflexor group. We have determined
previously that the GL constitutes 11% of the triceps surae PCSA
(33), and the triceps surae group was estimated to occupy 91% of the
plantarflexor PCSA
length joint angle relationship provided by Maganaris",MA=4.61 ± .32 cm,3,YNG,Normal,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,
4040,10.9,145,38.3,11,PF,CHD ,M,,,,,79.2,2268,,,,,,,,,,,,,0,CHD,Normal,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,
4040,10.9,145,38.3,11,GL,CHD ,M,V,64.5,4.2,15.5,,242.5,15.9,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Coactivation correction","MRI at rest, JA correction",Tendon Force using relative PCSA,Force/rPCSA,,MA=3.46 ± 0.2 cm,3,CHD,Normal,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,
2938,25.3,176.4,79.1,12,PF,YNG,M,V,,,,179.9,3864.5,,"MRI, CSA x slice interval",US at MVC,Measured,,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,"To estimate the contribution of
the GL to Achilles tendon force, the relative PCSA of the GL within
the triceps surae (TS) was calculated, We have
previously determined that the GL constitutes 11% of the triceps surae
PCSA (31), and the TS group was estimated to represent 91% of the
total PF PCSA in the elderly (45); hence this seems to justify the
assumption that the TS PCSA represents the main PCSA of the PFs",,2,YNG,Normal,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,
2938,25.3,176.4,79.1,12,GL,YNG,M,V,185.6,5.5,32.3,,416.2,13.1,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,,,2,YNG,Normal,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,
2938,73.8,173.4,78.4,19,PF,OLD,M,,,,,107,2422.5,,,,,,,,,,,,,0,OLD,Normal,PF,Plantar Flexors,Slow,mixed,antigravity,ankle plantar flexor,knee flexor,Lower leg,
2938,73.8,173.4,78.4,19,GL,OLD,M,V,133.3,5,27.1,,258.2,9.2,"MRI, CSA x slice interval",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",MRI at rest,Tendon Force using relative PCSA,Force/rPCSA,,,2,OLD,Normal,GL,Gastrocnemius Lateralis,50/50,biarticular,antigravity,ankle plantar flexor,knee flexor,Lower leg,
2820,38,175,76,4,BIC,MID ,M,V,,,11.6,,,35.6,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,Tendon force- % contribution from literature,Force/ACSA,"The specific tension of the brachial biceps muscle was
calculated from 1) a contribution of 34 92 from this muscle
to MVC in elbow flexion (Hansen & Lindhard 1923); 2) a
ratio of 1: 7 between ""force arm"" (distance from center of
axis of rotation of the elbow joint at the condylus humeri
and the point at which the brachial biceps muscle attaches
tuberositas radii) and ""resistance arm"" (distance from the
condylus humeri to handgrap) (Wilkie 1950); 3) an increase
of 34% of the cross-sectional area of the flexed
arm (Ikai & Fukunaga 1968).",,5,MID,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2820,31,170,58,4,BIC,YNG ,F,V,,,8.7,,,29.9,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,Tendon force- % contribution from literature,Force/ACSA,,,5,YNG,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2745,21.6,175,71,11,VL,YNG UT EXP,M,V,724.8,,86.6,,2710,31.8,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,"The relative contribution
of the VL muscle to the maximal quadriceps force
was estimated from its relative PCSA with respect to the
entire quadriceps muscle group, which was based on data
from Narici et al. (1992)",,3,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2745,21.6,175,71,11,VL,YNG UT EXP,M,V,715.9,,84.9,,2740,32.6,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,,,3,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2745,21.6,175,71,11,QF,YNG UT EXP,M,,,,,290.7,7380,,,,,,,,,,,,"post training QF MVC
383.8 ± 56.1
post training QF patella force
9440 ± 1330",0,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2745,21.6,175,71,11,QF,YNG UT EXP,M,,,,,292.3,7460,,,,,,,,,,,,"post training QF MVC
365.4 ± 44.9
post training QF patella force
8780 ± 1330",0,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2745,26.6,178,75.7,8,VL,YNG UT Control,M,V,,,87.2,,2720,31.6,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,,,3,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2745,26.6,178,75.7,8,QF,YNG UT Control,M,,,,,298,7290,,,,,,,,,,,,"post training QF MVC
296 ± 30.2
post training QF patella force
7040 ± 1000",0,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2745,21.6,175,71,11,VL,YNG T EXP,M,V,780,,88.7,,3510,40,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,,,3,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2745,21.6,175,71,11,VL,YNG T EXP,M,V,763.7,,91.5,,3290,36.2,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,,,3,YNG,Trained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2745,26.6,178,75.7,8,VL,YNG T Control,M,V,,,86.8,,2640,30.5,"MRI, CSA x slice interval",US at rest,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction","MRI at rest, MVC & JA correction",Tendon Force using relative PCSA,Force/rPCSA,,,3,YNG,Untrained,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
2672,28,173,68,7,QF,YNG ,Mixed,S,900,5.6,145,166,3532,25,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC from stimulation,"Literature value at experimental JA, MVC & cadaver shrinkinge correction",Tendon Force ,Force/rPCSA,"Stimulated to produce 75% of MVIT, Volume calculated using activated CSA, VL architecture used in ST calculation","the moment arm was derived
from cadavers and knee joints of able bodies, 0.04 m, at
the same knee joint angle used in our study (Baltzopou-
los 1995; Wickiewicz et al. 1983, 1984).",6,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2672,28,173,68,7,QF,YNG ,Mixed,S,500,6,83,78,1660,20,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC from stimulation,"Literature value at experimental JA, MVC & cadaver shrinkinge correction",Tendon Force ,Force/rPCSA,,,6,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2672,28,173,68,7,QF,YNG ,Mixed,S,1000,5.7,171,138,2936,17,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC from stimulation,"Literature value at experimental JA, MVC & cadaver shrinkinge correction",Tendon Force ,Force/rPCSA,,,6,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2672,28,173,68,7,QF,YNG ,Mixed,S,600,5.8,101,110,2340,26,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC from stimulation,"Literature value at experimental JA, MVC & cadaver shrinkinge correction",Tendon Force ,Force/rPCSA,,,6,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
2672,28,173,68,7,QF,YNG ,Mixed,S,1900,7.1,253,,,20,"MRI, CSA x slice interval",MRI muscle length x literature ratio,Literature value,PCSA,(Muscle vol/Fiber length)*cos(θ),max MVC from stimulation,"Literature value at experimental JA, MVC & cadaver shrinkinge correction",Tendon Force ,Force/rPCSA,,,6,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4205,22,179,78.3,18,VL,YNG ,M,V,604,8.2,74.7,,1704,23.6,"US, ACSA & literature regression relationship",US at MVC,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC + ITT, Activation & Coactivation correction",Xray at MVC JA,"Tendon force, % contribution from literature",Force/rPCSA,," With the VL being
one of the larger muscles in the body, invariably, the dimensions of the
probe was not large enough to capture a full fascicle; for these cases,
linear extrapolation was used to determine fascicle length, as little
error (2–7%) is observed at the midpoint of the muscle 


coactivation measured",2,YNG,Normal,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4205,22,179,78.3,18,KE,YNG ,M,,,,,287,7296,,,,,,,,Xray at MVC JA,,,,,0,YNG,Normal,,,,,,,,,
4050,27,180.7,72.8,11,QF,YNG UT,M,V,1676,7,,282.6,,42.6,"MRI, CSA x slice interval",Literature value,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Gravity correction",Literature value at experimental JA,"Tendon force, % contribution from literature",Force/rPCSA,ratio of patella force to QF force of 0.7 at 70 deg,,7,YNG,Untrained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4050,27,180.7,72.8,11,QF,YNG T,M,V,1841,7,,327,,45.3,"MRI, CSA x slice interval",Literature value,Measured,PCSA,(Muscle vol/Fiber length)*cos(θ),"max MVC, Gravity correction",Literature value at experimental JA,"Tendon force, % contribution from literature",Force/rPCSA,,,7,YNG,Trained,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
4204,34,174,74.1,6,VL,YNG ,M,,585.7,,62.4,,1451.9,23.7,"MRI, CSA x slice interval",MRI at rest,Measured,PCSA,(vol/muscle thickness)*sin(alpha),,Literature value at experimental JA,Force equilibrium model  and Tendon Force using relative PCSA,Force/rPCSA,load cell mounted to ankle.  MVC measured at static angles between 90-120 in 5 deg interval. only MVC used.  MA of external force (MAref) = external force MA  + internal knee COR measured from MRI. ,"formula used in the present study cor- 
responds to the formula for non-reduced physiological 
cross-sectional area of Alexander and Vernon (1975), as 
in their study n.a = (m/p*t
sin 0 (where n = number of 
fibres and a= cross-sectional area of each fibre) and 
should thus correspond to the non-reduced physiological 
cross-sectional area calculated by Haxton (1944).",4,YNG,Normal,VL,Vastus Lateralis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4204,34,174,74.1,6,VI,YNG ,M,,574,,83.5,,1997.1,24.1,"MRI, CSA x slice interval",MRI at rest,Measured,PCSA,(vol/muscle thickness)*sin(alpha),,Literature value at experimental JA,Force equilibrium model  and Tendon Force using relative PCSA,Force/rPCSA,MA of patella tendon (MApat) obtained from literature.,,4,YNG,Normal,VI,Vastus Intermedius,60/40,monoarticular,antigravity,knee extensor,,Thigh,
4204,34,174,74.1,6,VM,YNG ,M,,424.5,,68,,1913.2,27.9,"MRI, CSA x slice interval",MRI at rest,Measured,PCSA,(vol/muscle thickness)*sin(alpha),,Literature value at experimental JA,Force equilibrium model  and Tendon Force using relative PCSA,Force/rPCSA,,,4,YNG,Normal,VM,Vastus Medialis,Slow,monoarticular,antigravity,knee extensor,,Thigh,
4204,34,174,74.1,6,RF,YNG ,M,,238.7,,66.2,,1601.3,24.3,"MRI, CSA x slice interval",MRI at rest,Measured,PCSA,(vol/muscle thickness)*sin(alpha),,Literature value at experimental JA,Force equilibrium model  and Tendon Force using relative PCSA,Force/rPCSA,,,4,YNG,Normal,RF,Rectus Femoris,60/40,biarticular,antigravity,knee extensor,hip flexor,Thigh,
4204,34,174,74.1,6,QF,YNG ,M,,,,,,6366.5,,,,,,,,,,,,,0,YNG,Normal,QF,Quadriceps Femoris,60/40,mixed,antigravity,knee extensor,hip flexor,Thigh,
3042,23.9,169.9,69.2,14,EF,YNG ,Mixed,V,,,,,,69,,,,,CT ACSA,max MVC,Literature value at experimental JA,Tendon Force using relative (PCSA x MA),linear regression (muscle force vs CSA),,"assumption all muscles equally active

EF are bicep and brachialis",4,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
3042,23.9,169.9,69.2,14,BIC,YNG ,Mixed,,,,9.9,,,,,,,PCSA,,,,,,,,0,YNG,Normal,BIC,Biceps Brachii,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
3042,23.9,169.9,69.2,14,BRA,YNG ,Mixed,,,,11.5,,,,,,,PCSA,,,,,,,,0,YNG,Normal,BRA,Brachialis,Fast,monoarticular,non-antigravity,elbow flexor,,Upper arm,
2899,28,184,84,6,EF,YNG Control,,V,,,15.3,,,65.4,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,"Tendon force, % contribution from literature",Force/ACSA,Force was measured with a strain gauge inserted in the cable.,"EF- biceps brachii, brachialis",,YNG,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2899,68,176,78,7,EF,OLD Control,,V,,,12,,,60,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,"Tendon force, % contribution from literature",Force/ACSA,,,,OLD,Normal,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2899,69,171,74,6,EF,OLD T,,V,,,11.8,,,60.7,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,"Tendon force, % contribution from literature",Force/ACSA,,Swimming trained,,OLD,Trained,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2899,70,177,73,5,EF,OLD T,,V,,,12.2,,,62.4,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,"Tendon force, % contribution from literature",Force/ACSA,,running trained,,OLD,Trained,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
2899,68,174,79,6,EF,OLD T,,V,,,15.5,,,64.4,,,,ACSA,"CT ACSA, literature MVC correction",max MVC,Literature value at experimental JA,"Tendon force, % contribution from literature",Force/ACSA,,strength trained,,OLD,Trained,EF,Elbow Flexors,50/50,mixed,non-antigravity,elbow flexor,,Upper arm,
